Skip to main content

Event summary produced by The Globe and Mail Events team. The Globe’s editorial department was not involved.

Canada was a pioneer of stem cell research and today, innovators are developing clinical trials to test regenerative treatments for a range of illnesses including cardiac disease and Parkinson’s. At the same time, they’re navigating risks and considerations that often surround medical innovations.

The Globe and Mail hosted a webcast on November 30 to explore the promise and potential of stem cells. Speakers also discussed ethical issues, misinformation and the importance of rigorous evaluation in bringing new treatments to market.

Missed the live event or would like to view it again? Scroll down to the video player, below.

André Picard, health reporter and columnist with The Globe and Mail moderated the event and hosted the following speakers:

  • Gordon Keller, scientific co-founder with BlueRock Therapeutics and director of the McEwen Stem Cell Institute with UHN;
  • Cate Murray, executive director and COO of the Stem Cell Network;
  • Karen Lee, CEO of Parkinson Canada;
  • Jonathan Kimmelman, James McGill professor in the biomedical ethics unit with McGill University.

Read a summary of the event here

View the full webcast, below:

The Globe and Mail presented the webcast with sponsor support from Bayer.